Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:NKOCVE:ONVNYSE:PLXNYSE:SCD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNKONiko ResourcesC$0.00C$0.01▼C$0.12C$1.88MN/A466,121 shs3.98 million shsONVOronova EnergyC$0.07-7.1%C$0.06C$0.04▼C$0.10C$2.83MN/A75,187 shs64,713 shsPLXProtalix BioTherapeutics$1.55+3.0%$1.85$0.82▼$3.10$119.41M-0.23579,344 shs409,479 shsSCDLMP Capital and Income Fund$15.97+1.5%$15.72$13.35▼$17.96N/AN/A45,202 shs89,883 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNKONiko Resources0.00%0.00%0.00%0.00%0.00%ONVOronova Energy0.00%0.00%0.00%0.00%0.00%PLXProtalix BioTherapeutics+1.35%+6.38%-5.06%-42.31%+33.33%SCDLMP Capital and Income Fund-0.19%+1.75%-2.43%+1.62%+0.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNKONiko ResourcesN/AN/AN/AN/AN/AN/AN/AN/AONVOronova EnergyN/AN/AN/AN/AN/AN/AN/AN/APLXProtalix BioTherapeutics2.9306 of 5 stars3.53.00.00.01.90.01.9SCDLMP Capital and Income FundN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNKONiko Resources 0.00N/AN/AN/AONVOronova Energy 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$15.00870.87% UpsideSCDLMP Capital and Income Fund 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNKONiko ResourcesC$13.23M0.00N/A0.37C($4.06) per share0.00ONVOronova EnergyN/AN/AC$0.00 per share35.00C($0.01) per shareN/APLXProtalix BioTherapeutics$59.76M2.06$0.09 per share17.80$0.47 per share3.29SCDLMP Capital and Income Fund$87.86MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNKONiko ResourcesN/A-C$0.86N/AN/AN/AN/AN/AN/AN/AONVOronova EnergyN/A-C$0.02N/A∞N/AN/AN/AN/AN/APLXProtalix BioTherapeutics$8.31M$0.04N/A4.98N/A-21.03%-30.89%-11.74%N/ASCDLMP Capital and Income FundN/AN/A0.00∞N/AN/AN/AN/AN/ALatest NKO, PLX, ONV, PXEN, and SCD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNKONiko ResourcesN/AN/AN/AN/AN/AONVOronova EnergyN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ASCDLMP Capital and Income Fund$1.398.70%N/AN/AN/ALatest NKO, PLX, ONV, PXEN, and SCD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/19/2025SCDLMP Capital and Income Fundmonthly$0.129.1%8/22/20258/22/20259/2/20255/16/2025SCDLMP Capital and Income Fundmonthly$0.129.1%8/22/20258/22/20259/2/20256/17/2025SCDLMP Capital and Income Fund$0.129.2%6/23/20256/24/20257/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNKONiko ResourcesN/A0.010.01ONVOronova EnergyN/A0.190.19PLXProtalix BioTherapeuticsN/A1.981.27SCDLMP Capital and Income FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNKONiko ResourcesN/AONVOronova EnergyN/APLXProtalix BioTherapeutics16.53%SCDLMP Capital and Income FundN/AInsider OwnershipCompanyInsider OwnershipNKONiko ResourcesN/AONVOronova EnergyN/APLXProtalix BioTherapeutics6.50%SCDLMP Capital and Income FundN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNKONiko ResourcesN/A94.05 millionN/ANot OptionableONVOronova EnergyN/A43.60 millionN/ANot OptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionableSCDLMP Capital and Income Fund1,689N/AN/ANot OptionableNKO, PLX, ONV, PXEN, and SCD HeadlinesRecent News About These CompaniesCEF Insights: Equity And Income In Focus - The SCD ApproachJuly 1 at 12:27 PM | seekingalpha.comLMP Capital & Income Fund Inc. RtJune 16, 2025 | wsj.comLMP Capital and Income Fund Inc. Authorizes 1-For-3 Rights OfferingJune 2, 2025 | finance.yahoo.comInsider Buying: LMP Capital and Income Fund Inc. (NYSE:SCD) Director Acquires 700 Shares of StockMay 29, 2025 | insidertrades.comLMP Capital And Income Fund Inc. Q1 2025 CommentaryMay 16, 2025 | seekingalpha.comSCD: This Hybrid Tech/Energy CEF Raised The Distribution, Now Has A Big DiscountApril 21, 2025 | seekingalpha.comLMP Capital and Income Fund Inc. Announces Results of Annual Meeting of StockholdersApril 17, 2025 | gurufocus.comLMP Capital and Income Fund Inc. Announces Results of Annual Meeting of Stockholders | SCD ...April 17, 2025 | gurufocus.comLMP Capital And Income Fund Inc. Q4 2024 CommentaryMarch 27, 2025 | seekingalpha.comSCD: Continuing To Perform Well As Discount Narrows FurtherFebruary 26, 2025 | seekingalpha.comFebruary 3, 2025 | gurufocus.comLMP Capital and Income Fund Inc. (SCD or the Fund; CUSIP: 50208A102) Announces Notification of Sources of DistributionsFebruary 3, 2025 | investing.comTrend Tracker for (SCD)January 17, 2025 | news.stocktradersdaily.comNSCD: Monthly Paying CEF With Energy And Tech ExposureJanuary 7, 2025 | seekingalpha.comTrading (SCD) With Integrated Risk ControlsJanuary 7, 2025 | news.stocktradersdaily.comNNMAI: Very Attractive Yield, If It Is SustainableDecember 20, 2024 | seekingalpha.comWhen (SCD) Moves Investors should ListenDecember 17, 2024 | news.stocktradersdaily.comNDecember 2, 2024 | gurufocus.comLMP Capital and Income Fund Inc. (SCD or the Fund; CUSIP: 50208A102) Announces Notification of Sources of DistributionsDecember 2, 2024 | investing.comObjective long/short (SCD) ReportNovember 15, 2024 | news.stocktradersdaily.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeArcher's Midnight Air Taxi Soars, But Stock Doesn’t BudgeBy Jeffrey Neal Johnson | June 4, 2025View Archer's Midnight Air Taxi Soars, But Stock Doesn’t BudgeNKO, PLX, ONV, PXEN, and SCD Company DescriptionsNiko Resources TSE:NKONiko Resources Ltd. engages in the exploration, development, and production of oil and natural gas in India and Bangladesh. It primarily holds interests in the D6 Block consisting of Dhirubhai 1 and 3 Fields, MA Field, R cluster development project, satellite cluster development project, and MJ field development project located off the coastline of Andhra Pradesh, India; and the Block 9 in the central area of Bangladesh. The company was founded in 1987 and is headquartered in Calgary, Canada.Oronova Energy CVE:ONVC$0.06 -0.01 (-7.14%) As of 02/13/2020Oronova Energy Inc., a development stage company, engages in the acquisition, exploration, development, and production of crude oil and natural gas reserves in Latin America. It intends to seek for oil and gas opportunities in Latin America. The company was formerly known as Oronova Resource Corp. and changed its name to Oronova Energy Inc. in December 2016. Oronova Energy Inc. is based in Vancouver, Canada.Protalix BioTherapeutics NYSE:PLX$1.54 +0.05 (+3.00%) Closing price 03:54 PM EasternExtended Trading$1.54 0.00 (0.00%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.LMP Capital and Income Fund NYSE:SCD$15.97 +0.24 (+1.53%) As of 03:30 PM EasternLMP Capital and Income Fund Inc. is a closed ended balanced mutual fund launched and managed by Legg Mason Partners Fund Advisor, LLC. It is co-managed by Clearbridge Investments, LLC, Western Asset Management Company Limited, and Western Asset Management Company. The fund invests in public equity and fixed income markets across the globe. It seeks to invest in securities of companies operating across diversified sectors. The fund primarily invests in stocks of large-cap companies, intermediate period corporate bonds and notes rated at least A-, energy and non-energy master limited partnerships, and real estate investment trusts. It focuses on such factors as economic, market, or political conditions, fiscal and monetary policy, and security valuation to create its portfolio. The fund benchmarks the performance of its portfolio against the U.S. Aggregate Index and S&P 500 Index. It was formerly known as Salomon Brothers Capital and Income Fund Inc. LMP Capital and Income Fund Inc. was formed on November 12, 2003 and is domiciled in the United States. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
